Leqembi® Launches in South Korea
BioArctic AB (publ) (NASDAQ: BIOA B) has exciting news for those affected by Alzheimer's disease. Their partner, Eisai, has successfully launched Leqembi® (known generically as lecanemab) in South Korea. This launch follows the product's approval in the region earlier in May for treating adults experiencing mild cognitive impairment related to Alzheimer's or mild dementia.
The Need for Effective Alzheimer's Treatments
In South Korea, around 900,000 individuals were reported to be living with dementia in recent years. Alarmingly, it was found that one in ten people over the age of 65 suffer from dementia, and one in five deal with mild cognitive impairment. With Alzheimer's dementia accounting for roughly 70% of dementia cases, the need for effective treatments has never been clearer.
Eisai's Planned Strategy
Initially, Eisai is set to introduce Leqembi in the private market, which may significantly affect the treatment landscape for patients and healthcare providers. This strategic approach aims to enhance patient access to breakthrough therapies to manage Alzheimer's disease effectively.
How Leqembi® Works Against Alzheimer's Disease
Leqembi functions by selectively targeting and binding to both soluble and insoluble aggregates of amyloid-beta (A?), which are critical components of the plaques found in the brains of Alzheimer's patients. This mechanism leads to the reduction of harmful A? protofibrils and plaques, ultimately slowing the progression of the disease and improving cognitive function.
A Collaborative Effort Between BioArctic and Eisai
The development of Leqembi is a result of a long-term partnership between BioArctic and Eisai. Initially based on the pioneering work of Professor Lars Lannfelt, the antibody has undergone rigorous clinical development by Eisai. They have also taken the lead on obtaining market approvals and are responsible for the commercialization of lecanemab worldwide.
Regulatory Approvals and Global Expansion
Lecanemab has not only been approved in South Korea but also in several other countries, including the U.S., Japan, and several regions in Europe. The treatment's approval is grounded in robust clinical trial data, particularly from the global Clarity AD trial, which demonstrated significant results in reducing cognitive decline and meeting primary and secondary endpoints.
Future Prospects for Lecanemab
Eisai has applied for regulatory approval of lecanemab in many other countries. Recent developments indicate positive momentum, as a supplemental application for less frequent intravenous dosing has already been submitted to the FDA. These ongoing advancements reflect a commitment to making this treatment more convenient for patients, potentially enhancing its acceptance and utilization in clinical settings.
BioArctic's Innovative Research Agenda
In addition to Leqembi, BioArctic is focusing on an expansive research portfolio that includes innovative therapies for conditions such as Parkinson's disease and ALS. Their proprietary BrainTransporter™ technology is particularly inspiring, as it holds promise for improving the delivery of antibodies across the blood-brain barrier, which could be a game-changer in neurodegenerative disease treatment.
Caring for Patients with Alzheimer's Disease
As BioArctic and Eisai work together to bring Leqembi to patients, their commitment to improving the lives of those with Alzheimer's disease remains steadfast. With a deep understanding of the challenges faced by patients and families, they aim to set new standards in Alzheimer's care through continued innovation and collaboration.
Frequently Asked Questions
What is Leqembi®?
Leqembi® (lecanemab) is a monoclonal antibody intended for treating cognitive impairment due to Alzheimer’s disease.
How does Leqembi® work?
Leqembi works by targeting amyloid-beta aggregates, thereby reducing plaques and slowing cognitive decline associated with Alzheimer’s disease.
Who developed Leqembi®?
Leqembi was developed through a collaboration between BioArctic and Eisai, based on early research by Professor Lars Lannfelt.
In which countries is Leqembi® approved?
Leqembi is currently approved in the U.S., South Korea, Japan, China, and several European regions.
What is the significance of this launch in South Korea?
The launch in South Korea represents a critical step in addressing the growing need for effective Alzheimer's treatments, providing new options for patients and caregivers.
